TRVI
Trevi Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2019-05-07
$13.86
+0.23 (+1.69%)
last quote
Want the full multi-source brief on TRVI?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$13.86
High
$14.23
Low
$13.74
Previous close
$13.63
Fundamentals
Market cap
$1.97B
P/E (TTM)
—
P/S (TTM)
—
P/B
8.76x
Gross margin
—
Operating margin
—
Net margin
—
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-23.59%
52W high
$20.22
52W low
$9.82
Beta
1.18x
Industry peers
by market cap
Upcoming earnings
next 60 days
2026-11-11in 6 days
Q3 2026EPS est $-0.14
2026-11-09in 4 days
Q3 2026EPS est $-0.14
Recent SEC filings
CIK 1563880filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 1d
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and
Yahoo · 2d
Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book Value
Trevi Therapeutics has seen its stock trace a dramatic path in recent years, which naturally raises a simple question for investors who care about balance sheets. Is the latest share price grounded in what the company’s book value can support. Over the past 5 years, Trevi Therapeutics has delivered a very large share price gain, so any holder today has to ask how much of that move is actually back
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial